

PRESS RELEASE

Wednesday, 29th July 2020, Mumbai

GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended June 30, 2020

Profit After Tax +3%

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 30th June 2020. Revenue for the quarter came in at Rs.649 crores. Profit After Tax at Rs 111 crores

recorded a growth of 3%.

Commenting on the results, **Sridhar Venkatesh**, **Managing Director**, **GlaxoSmithKline Pharmaceuticals Limited** said.

"We demonstrated extreme resilience in the face of the unprecedented business environment created by the Covid-19 pandemic. While keeping employee safety and well-being as our topmost concern and remaining committed to patients' access to medicines, we were the first multi-national company to get back to the field once the lockdown restrictions were lifted by the government. It is encouraging for us to note that during such challenging times our market share has grown despite the established brands not performing up to our expectations due to prevailing market conditions. The FY21 is a promising year for GSK as we are set to introduce new assets and these launches, as it happens post regulatory approvals, shall contribute to GSK firming its position as a science- and innovation-led biopharmaceutical company."

About GlaxoSmithKline Pharmaceuticals Limited

Glaxo SmithKline Pharmaceuticals Limited is a subsidiary of Glaxo SmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts: Ransom D'Souza Vice President Corporate Communications and Government Affairs Email: ransom.a.dsouza@gsk.com

Tel: +91 22 24959203